ACADIA Pharmaceuticals IncNASDAQ:ACAD
- LAST PRICE15.5100
- TODAY'S CHANGE (%)-0.0900 (-0.5769%)
- Bid / Lots15.5000/ 3
- Ask / Lots15.5100/ 1
- Open / Previous Close15.5300 / 15.6000
- Day Range
- 52 Week Range
- Volume504,375
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ACAD |
|---|---|---|
| 09:32 ET | 28176 | 15.33 |
| 09:34 ET | 1891 | 15.41 |
| 09:36 ET | 712 | 15.39 |
| 09:38 ET | 901 | 15.47 |
| 09:39 ET | 200 | 15.425 |
| 09:41 ET | 901 | 15.4516 |
| 09:43 ET | 500 | 15.5 |
| 09:45 ET | 750 | 15.436 |
| 09:48 ET | 1042 | 15.42 |
| 09:50 ET | 800 | 15.44 |
| 09:52 ET | 1067 | 15.49 |
| 09:54 ET | 200 | 15.5 |
| 09:56 ET | 670 | 15.49 |
| 09:57 ET | 817 | 15.5 |
| 09:59 ET | 3100 | 15.47 |
| 10:01 ET | 1020 | 15.51 |
| 10:03 ET | 1041 | 15.52 |
| 10:06 ET | 1430 | 15.525 |
| 10:08 ET | 1500 | 15.485 |
| 10:10 ET | 5587 | 15.4801 |
| 10:12 ET | 500 | 15.5 |
| 10:14 ET | 1100 | 15.49 |
| 10:15 ET | 900 | 15.46 |
| 10:17 ET | 2414 | 15.44 |
| 10:19 ET | 300 | 15.4 |
| 10:21 ET | 1500 | 15.41 |
| 10:24 ET | 1250 | 15.4 |
| 10:26 ET | 1400 | 15.38 |
| 10:28 ET | 4260 | 15.4 |
| 10:30 ET | 1460 | 15.38 |
| 10:32 ET | 2389 | 15.38 |
| 10:33 ET | 5888 | 15.34 |
| 10:35 ET | 1499 | 15.3501 |
| 10:37 ET | 100 | 15.34 |
| 10:39 ET | 800 | 15.34 |
| 10:42 ET | 2208 | 15.3506 |
| 10:44 ET | 1200 | 15.35 |
| 10:46 ET | 3648 | 15.35 |
| 10:48 ET | 600 | 15.35 |
| 10:50 ET | 2222 | 15.34 |
| 10:51 ET | 3671 | 15.35 |
| 10:53 ET | 82448 | 15.4 |
| 10:55 ET | 24921 | 15.415 |
| 10:57 ET | 3637 | 15.405 |
| 11:00 ET | 6017 | 15.39 |
| 11:02 ET | 8906 | 15.43 |
| 11:04 ET | 8128 | 15.41 |
| 11:06 ET | 2627 | 15.47 |
| 11:08 ET | 900 | 15.48 |
| 11:09 ET | 5057 | 15.48 |
| 11:11 ET | 305 | 15.46 |
| 11:13 ET | 4514 | 15.425 |
| 11:15 ET | 1713 | 15.43 |
| 11:18 ET | 4376 | 15.47 |
| 11:20 ET | 200 | 15.46 |
| 11:22 ET | 1500 | 15.46 |
| 11:24 ET | 5753 | 15.475 |
| 11:26 ET | 3254 | 15.47 |
| 11:27 ET | 52557 | 15.52 |
| 11:29 ET | 3700 | 15.48 |
| 11:31 ET | 2000 | 15.5 |
| 11:33 ET | 1350 | 15.52 |
| 11:36 ET | 6127 | 15.51 |
| 11:38 ET | 20034 | 15.47 |
| 11:40 ET | 1984 | 15.46 |
| 11:42 ET | 1200 | 15.48 |
| 11:44 ET | 3019 | 15.5 |
| 11:45 ET | 4317 | 15.52 |
| 11:47 ET | 2728 | 15.51 |
| 11:49 ET | 2100 | 15.535 |
| 11:51 ET | 6741 | 15.53 |
| 11:54 ET | 18852 | 15.53 |
| 11:56 ET | 2525 | 15.555 |
| 11:58 ET | 2207 | 15.555 |
| 12:00 ET | 2923 | 15.525 |
| 12:02 ET | 1156 | 15.51 |
| 12:03 ET | 1500 | 15.51 |
| 12:05 ET | 2650 | 15.4976 |
| 12:07 ET | 3531 | 15.4895 |
| 12:09 ET | 1400 | 15.505 |
| 12:12 ET | 1000 | 15.505 |
| 12:14 ET | 2000 | 15.49 |
| 12:16 ET | 1734 | 15.48 |
| 12:18 ET | 2077 | 15.51 |
| 12:20 ET | 200 | 15.51 |
| 12:21 ET | 600 | 15.51 |
Yesterday
DJ ACADIA Pharmaceuticals Price Target Maintained With a $29.00/Share by RBC Capital, from 10:35AM ET on Tuesday Jun 25, 2024 by Dow Jones
10:35AM ET on Tuesday Jun 25, 2024 by Dow Jones
Jun 18, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
ACADIA Pharmaceuticals Inc | 2.6B | -1,205.1x | --- |
Azenta Inc | 2.9B | -19.8x | --- |
PTC Therapeutics Inc | 2.7B | -4.6x | --- |
Guardant Health Inc | 3.6B | -7.4x | --- |
Novavax Inc | 2.0B | -4.3x | --- |
Amicus Therapeutics Inc | 2.9B | -19.7x | --- |
Company Information
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Contact Information
- Headquarters
- 12830 El Camino Real, Suite 400SAN DIEGO, CA, United States 92130
- Phone
- 858-558-2871
- Fax
- 858-558-2872
Executives
- Independent Chairman of the Board
- Stephen Biggar
- Chief Executive Officer, Director
- Stephen Davis
- Chief Financial Officer, Executive Vice President
- Mark Schneyer
- Chief Operating Officer, Executive Vice President, Head of Commercial
- Brendan Teehan
- Executive Vice President, Company Secretary and Chief Legal Officer
- Jennifer Rhodes
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.6B |
|---|---|
Revenue (TTM) | $813.8M |
Shares Outstanding | 165.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.37 |
EPS | $-0.01 |
Book Value | $2.62 |
P/E Ratio | -1,205.1x |
Price/Sales (TTM) | 3.2 |
Price/Cash Flow (TTM) | 288.2x |
Operating Margin | -0.56% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
